Everything Is Tuberculosis by John Green: A Review

John Green built a career on the idea that teenagers deserve to be talked to like they can handle complicated things — grief, cancer, the fact that the universe doesn't owe anyone a fair ending. "Everything Is Tuberculosis" applies that same instinct to adults, and to a disease most of us think of as a Victorian novel's death sentence rather than a present-tense global emergency. It is not what you expect from the author of "The Fault in Our Stars," and that is the best thing about it.

The book opens in Sierra Leone, in a hospital ward, with a teenager named Henry Reider. Henry has drug-resistant tuberculosis. He is charming, funny, sharp enough to needle Green in the way a smart teenager needles anyone who's clearly trying too hard to seem casual. Green met him while filming a documentary years earlier, and Henry's survival — improbable, expensive, dependent on medication that should have been available to him from the start and wasn't — becomes the spine the rest of the book hangs on.

The History Half of the Book

Green is not a historian by training, and he doesn't pretend to be one — he's upfront that he came to this material as an obsessive, the same way he came to obsess over the QI trivia database or the history of the ballpoint pen on his old podcast. But the research holds up. He traces tuberculosis from a disease romanticized in nineteenth-century literature — the pale, consumptive genius, coughing blood into a handkerchief in a Paris garret — to its rebranding as a disease of poverty once effective antibiotics made it curable for anyone who could afford treatment. That rebranding is the book's real argument: TB stopped being tragic and started being embarrassing, a disease associated with prisons, refugee camps, and countries poor enough that pharmaceutical companies didn't bother pricing a cure within reach.

The chapters on the discovery of streptomycin and the decades of underinvestment that followed are the strongest writing in the book — clear, angry in a controlled way, willing to name pharmaceutical companies and specific pricing decisions rather than gesturing vaguely at "the system." If you've read Green's YA novels, this is the same moral clarity, aimed at a different, more solvable target.

Where It Gets Uneven

The book moves between three registers — Henry's personal story, the history of TB, and Green's own advocacy work pressuring drug manufacturers over pricing — and the transitions between them are not always smooth. A chapter that's deep in nineteenth-century medical history will suddenly cut back to a text message exchange with Henry, and the tonal whiplash is real. Readers who came for a tight historical narrative might find themselves impatient during the advocacy sections; readers who came for Henry's story might find the historical detours a little long. It's a book that's trying to be three things at once, and it mostly succeeds, but "mostly" is doing some work in that sentence.

Who This Is Actually For

If you liked Green's essay collection "The Anthropocene Reviewed," this is a natural next step — same voice, more focused subject, higher stakes. If you're looking for a purely narrative medical-history book in the vein of "The Emperor of All Maladies," the personal-advocacy sections will feel like a detour. And if you've never read Green before and only know him from the YA adaptations, this is a genuinely good entry point into his nonfiction — it doesn't require any familiarity with his novels, and the writing is more direct than his fiction tends to be.

The Drug Pricing Chapters, Specifically

The most quietly enraging material in the book isn't the nineteenth-century history — it's the twenty-first-century pricing. Green walks through the actual cost structure of the drugs used to treat drug-resistant TB, the ones Henry needed to survive, and lays out how a treatment course that costs a few hundred dollars to manufacture ends up priced far beyond what most patients in the countries hit hardest by TB can access without external intervention. He names the manufacturer. He walks through the patent extensions. He's specific in a way that a lot of "big pharma is bad" writing isn't, and that specificity is what makes the advocacy sections land instead of reading like a lecture.

This is also where the book becomes, functionally, a piece of activist writing rather than pure narrative nonfiction — Green has been vocal about pressuring the manufacturer directly, and the book documents some of that pressure campaign in real time. Readers who want their nonfiction to stay in a more traditional observer's voice may find this section tonally jarring after the more restrained historical chapters. We didn't; we thought it was the point.

How It Compares to Green's Earlier Work

Longtime readers of Green's YouTube and podcast work — Crash Course, the Nerdfighteria community, his "Anthropocene Reviewed" essays — will recognize the voice immediately: curious, slightly self-deprecating about his own obsessive research habits, willing to sit with contradictions rather than resolve them neatly. What's different here is the stakes. "The Anthropocene Reviewed" reviewed things like Diet Dr Pepper and Canada geese on a five-star scale, charming precisely because the subjects were low-stakes. Tuberculosis is not a low-stakes subject, and Green seems aware that the charm has to be earned differently this time — there's less of the ironic distance and more direct address to the reader about what to actually do with the anger the book is trying to generate.

A Note on the Ending

Without spoiling where Henry's story lands, the closing chapters resist the easy narrative arc that a book like this could have taken — TB survivor as inspirational bow on top of a policy argument. Green is more careful than that, and the book is better for it. It ends less with resolution than with a clear, specific ask: here is what changed, here is what still hasn't, here is exactly who could change it next. It's an unusual note to end a book on, and it's the right one for this particular book.

The Physical Book Itself

A small but real detail: the hardcover includes several black-and-white photographs interspersed through the chapters — Henry, the ward, archival images from the history of sanatorium treatment — and they land harder in print than they would on a Kindle screen. If you're choosing between formats and don't have a strong preference, we'd lean print for this one specifically because of how the images are integrated into the reading experience, not just appended as a photo insert in the middle of the book the way older non-fiction often does it.

The endnotes are also worth reading, which isn't true of every popular-science-adjacent book. Green cites his sources specifically enough that a curious reader can actually follow up on individual claims — the streptomycin pricing history, in particular, has enough of a paper trail cited that we were able to independently verify the broad strokes of his account rather than taking it on faith.

The Details

Our Take

This isn't the book to hand someone who wants a tidy, single-genre read. It's the book to hand someone who's willing to follow an argument through three different registers because the person making it clearly cares more about the outcome than the form. We gave it an 8.9 — not a perfect score, because the seams show in places, but a book that made us look up TB drug pricing on our own after finishing it is doing something most nonfiction doesn't manage.

Related reading: see our list of The Best Non-Fiction Books of 2026 for five more titles in this vein, and our guide on How to Read More Non-Fiction Without Losing Interest Halfway Through if books like this one tend to lose you around chapter six.